CTLA4 and esophageal squamous cell carcinoma: In this phase I trial, the combination of KN046, a dual immune checkpoint inhibitor targeting PD-L1 and CTLA-4, with chemotherapy and palliative radiotherapy has shown feasibility for patients with advanced ESCC, exhibiting a commendable safety profile.